

REMARKS

Claims 77-85 were pending. Claim 77 has been amended. Claims 86 and 87, which are dependent on Claim 77, are added. No new matter is added. Applicants respectfully request reconsideration of the rejections.

The specification has been amended to correct the informalities noted by the Examiner. Withdrawal of the objection is requested.

Claims 77-85 have been rejected under 35 U.S.C. 112, first paragraph as failing to comply with the written description requirement. Without conceding to the correctness of the rejection, and while maintaining the right to refile claims of the previously submitted scope, in the interests of furthering prosecution Applicants have amended the present claims to recite an antineoplastic agent selected from at least one of paclitaxel and docetaxel. The Office Action, at page 4, states that Figure 23 and Figure 28 provide support for a synergistic combination *in vivo* using an agent selected from paclitaxel and taxotere. Withdrawal of the rejection is requested.


CONCLUSION

Applicants submit that all of the claims are now in condition for allowance, which action is requested. If the Examiner finds that a Telephone Conference would expedite the prosecution of this application, she is invited to telephone the undersigned at the number provided.

The Commissioner is hereby authorized to charge any other fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815, order number CELL-017.

Respectfully submitted,

Date: September 16, 2004

By: 
Pamela J. Sherwood, Ph.D.
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, CA 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231